HeraMED Ltd. (AU:HMD)
ASX:HMD
HMD Stock Chart & Stats
AU$0.04
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.04
AU$0.00(0.00%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.06
Previous CloseN/A
Volume370.09K
Average Volume (3M)1.96M
Market Cap
AU$55.81M
Enterprise ValueAU$26.11M
Total Cash (Recent Filing)AU$914.65K
Total Debt (Recent Filing)AU$282.39K
Price to Earnings (P/E)―
Beta2.25
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,116,287,200
10 Day Avg. Volume1,195,844
30 Day Avg. Volume1,958,766
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)27.61
Price to Sales (P/S)131.32
P/FCF Ratio-10.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Niche Digital Women's Health FocusHeraMED's explicit focus on pregnancy and maternal remote monitoring is a durable strategic position. The company's software and connected-care capabilities (data capture and clinical decision support) align with long-term structural trends toward telehealth, enabling sustained customer stickiness and differentiated product-market fit if adoption grows.
Material Gross Margin Improvement (~60%)A sustained ~60% gross margin materially strengthens unit economics and indicates the core product/service can scale profitably at the gross level. If management controls operating overhead and leverages this margin through volume or subscription models, the company has a clearer path to operating leverage over the medium term.
Deleveraged Balance Sheet (zero Debt By 2025)Elimination of debt and a positive equity position reduces near-term solvency risk and interest burden. A cleaner balance sheet improves flexibility to pursue strategic partnerships or incremental R&D without immediate debt servicing constraints, making the company more resilient while it works to convert margins into operating profits.
Bears Say
Persistent Negative Operating And Free Cash FlowOperating and free cash flow have been negative each year, creating ongoing funding needs. Persistent cash burn increases reliance on external financing, risks dilution, and limits the company's ability to invest in sales, marketing, or product development required to scale revenues and realize margin potential over the medium term.
Consistent Net Losses And Deeply Negative MarginsThe company reports sustained operating and net losses, with net margins deeply negative across periods. Continued unprofitability erodes equity, hinders reinvestment from internal funds, and lengthens the time required to reach self-sustaining operations absent clear and sustained revenue growth or cost restructuring.
Volatile And Recently Declining Revenue TrendRevenue volatility and recent contraction (2025 down ~5% vs. 2024; multiyear growth negative) weaken scale economics and make it harder to absorb fixed costs. Without stable top-line growth, improved gross margins may not translate to operating profitability, prolonging the company's reliance on external capital.
HeraMED Ltd. News
HMD FAQ
What was HeraMED Ltd.’s price range in the past 12 months?
HeraMED Ltd. lowest share price was <AU$0.01 and its highest was AU$0.06 in the past 12 months.
What is HeraMED Ltd.’s market cap?
HeraMED Ltd.’s market cap is AU$55.81M.
When is HeraMED Ltd.’s upcoming earnings report date?
HeraMED Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 151 days.
How were HeraMED Ltd.’s earnings last quarter?
HeraMED Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.002.
Is HeraMED Ltd. overvalued?
According to Wall Street analysts HeraMED Ltd.’s price is currently Overvalued.
Does HeraMED Ltd. pay dividends?
HeraMED Ltd. does not currently pay dividends.
What is HeraMED Ltd.’s EPS estimate?
HeraMED Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does HeraMED Ltd. have?
HeraMED Ltd. has 1,116,287,200 shares outstanding.
What happened to HeraMED Ltd.’s price movement after its last earnings report?
HeraMED Ltd. reported an EPS of -AU$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.556%.
Which hedge fund is a major shareholder of HeraMED Ltd.?
Currently, no hedge funds are holding shares in AU:HMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HeraMED Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:HMD Sentiment 62%
Sector Average 69%
Sector Average 69%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
―
20 days / 200 days
Momentum
100.00%
12-Months-Change
Fundamentals
Return on Equity
-417.72%
Trailing 12-Months
Asset Growth
-68.43%
Trailing 12-Months
Company Description
HeraMED Ltd.
HeraMED Limited, together with its subsidiaries, develops, manufactures, and sells foetal heart beat monitors and other pregnancy monitoring solutions for home use in Australia, Europe, and Israel. The company provides HeraBEAT, a fetal heart rate monitor use by an expectant mother to monitor their fetus' heartbeat; and HeraCARE, a digital pregnancy monitor platform for the creation and implementation of digital health solutions for maternity care management. It also develops EchoBEAT, the next generation of its home-oriented pregnancy monitoring devices; and Orion, an artificial intelligence powered pregnancy monitoring system for pregnancy monitoring analysis. The company has a collaboration agreement with Mayo Clinic for the development of its HeraCARE pregnancy management platform. HeraMED Limited was incorporated in 2011 and is headquartered in Netanya, Israel.